Download PDF
Digestive Disease Interventions 2021; 05(02): 103-112
DOI: 10.1055/s-0041-1729755
Review Article

Radioembolization for Metastatic Neuroendocrine Tumors

Ghassan El-Haddad 
1   Radionuclide Therapy Program, Department of Diagnostic Imaging and Interventional Radiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
,
Jonathan Strosberg 
2   Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Transarterial radioembolization (TARE) using β-emitting yttrium-90 microspheres has been used for decades in patients with liver-dominant unresectable metastatic neuroendocrine tumors (mNETs). TARE is one of the embolotherapies supported by the National Comprehensive Cancer Network, among other guidelines, for progressive or symptomatic liver-dominant mNETs. Initial studies with relatively short-term follow-up have indicated that TARE is likely to be at least as effective in controlling symptoms and/or disease progression in the liver as bland or chemoembolization. However, more recent data have shed new light on the risk of long-term hepatotoxicity in patients with mNETs treated with TARE. In this article, we will discuss rationale for TARE, clinical indications, outcomes, and toxicity, as well as new strategies to enhance efficacy of TARE while reducing its toxicity in the treatment of liver-dominant mNETs.

Keywords

radioembolization - yttrium-90 - neuroendocrine tumor


Publication History

Received: 03 March 2021

Accepted: 15 March 2021

Article published online:
17 May 2021

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Dasari A, Shen C, Halperin D. et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 2017; 3 (10) 1335-1342
    CrossrefPubMedGoogle Scholar
  • 2 Riihimäki M, Hemminki A, Sundquist K. et al. The epidemiology of metastases in neuroendocrine tumors. Int J Cancer 2016; 139 (12) 2679-2686
    CrossrefPubMedGoogle Scholar
  • 3 Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003; 97 (04) 934-959
    CrossrefPubMedGoogle Scholar
  • 4 Oberg K, Eriksson B. Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol 2005; 19 (05) 753-781
    CrossrefPubMedGoogle Scholar
  • 5 Janson ET, Holmberg L, Stridsberg M. et al. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol 1997; 8 (07) 685-690
    CrossrefPubMedGoogle Scholar
  • 6 Yao JC, Eisner MP, Leary C. et al. Population-based study of islet cell carcinoma. Ann Surg Oncol 2007; 14 (12) 3492-3500
    CrossrefPubMedGoogle Scholar
  • 7 Halperin DM, Shen C, Dasari A. et al. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol 2017; 18 (04) 525-534
    CrossrefPubMedGoogle Scholar
  • 8 Mota JM, Sousa LG, Riechelmann RP. Complications from carcinoid syndrome: review of the current evidence. Ecancermedicalscience 2016; 10: 662
    PubMedGoogle Scholar
  • 9 Tomassetti P, Campana D, Piscitelli L. et al. Endocrine pancreatic tumors: factors correlated with survival. Ann Oncol 2005; 16 (11) 1806-1810
    CrossrefPubMedGoogle Scholar
  • 10 Pavel M, O'Toole D, Costa F. et al; Vienna Consensus Conference participants. ENETS Consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology 2016; 103 (02) 172-185
    CrossrefPubMedGoogle Scholar
  • 11 Strosberg JR, Halfdanarson TR, Bellizzi AM. et al. The North American Neuroendocrine Tumor Society Consensus Guidelines for surveillance and medical management of midgut neuroendocrine tumors. Pancreas 2017; 46 (06) 707-714
    CrossrefPubMedGoogle Scholar
  • 12 Gaba RC. Chemoembolization practice patterns and technical methods among interventional radiologists: results of an online survey. AJR Am J Roentgenol 2012; 198 (03) 692-699
    CrossrefPubMedGoogle Scholar
  • 13 Shah MH, Goldner WS, Halfdanarson TR. et al. NCCN Guidelines insights: neuroendocrine and adrenal tumors, version 2.2018. J Natl Compr Canc Netw 2018; 16 (06) 693-702
    CrossrefPubMedGoogle Scholar
  • 14 Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol 1954; 30 (05) 969-977
    PubMedGoogle Scholar
  • 15 Campbell AM, Bailey IH, Burton MA. Tumour dosimetry in human liver following hepatic yttrium-90 microsphere therapy. Phys Med Biol 2001; 46 (02) 487-498
    CrossrefPubMedGoogle Scholar
  • 16 Kennedy AS, Nutting C, Coldwell D. et al. Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys 2004; 60 (05) 1552-1563
    CrossrefPubMedGoogle Scholar
  • 17 Gulpinar B, Peker E, Kul M. et al. Liver metastases of neuroendocrine tumors: is it possible to diagnose different histologic subtypes depending on multiphasic CT features?. Abdom Radiol (NY) 2019; 44 (06) 2147-2155
    CrossrefPubMedGoogle Scholar
  • 18 Neperud J, Mahvash A, Garg N. et al. Can imaging patterns of neuroendocrine hepatic metastases predict response yttrium-90 radioembolotherapy?. World J Radiol 2013; 5 (06) 241-247
    CrossrefPubMedGoogle Scholar
  • 19 Sato KT, Omary RA, Takehana C. et al. The role of tumor vascularity in predicting survival after yttrium-90 radioembolization for liver metastases. J Vasc Interv Radiol 2009; 20 (12) 1564-1569
    CrossrefPubMedGoogle Scholar
  • 20 Boas FE, Brody LA, Erinjeri JP. et al. Quantitative measurements of enhancement on preprocedure triphasic CT can predict response of colorectal liver metastases to radioembolization. AJR Am J Roentgenol 2016; 207 (03) 671-675
    CrossrefPubMedGoogle Scholar
  • 21 Morsbach F, Sah BR, Spring L. et al. Perfusion CT best predicts outcome after radioembolization of liver metastases: a comparison of radionuclide and CT imaging techniques. Eur Radiol 2014; 24 (07) 1455-1465
    CrossrefPubMedGoogle Scholar
  • 22 Sato K, Lewandowski RJ, Bui JT. et al. Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere): assessment of hepatic arterial embolization. Cardiovasc Intervent Radiol 2006; 29 (04) 522-529
    CrossrefPubMedGoogle Scholar
  • 23 Vesselle G, Petit I, Boucebci S. et al. Radioembolization with yttrium-90 microspheres work up: practical approach and literature review. Diagn Interv Imaging 2015; 96 (06) 547-562
    CrossrefPubMedGoogle Scholar
  • 24 Salem R, Lewandowski RJ, Sato KT. et al. Technical aspects of radioembolization with 90Y microspheres. Tech Vasc Interv Radiol 2007; 10 (01) 12-29
    CrossrefPubMedGoogle Scholar
  • 25 Morgan B, Kennedy AS, Lewington V. et al. Intra-arterial brachytherapy of hepatic malignancies: watch the flow. Nat Rev Clin Oncol 2011; 8 (02) 115-120
    CrossrefPubMedGoogle Scholar
  • 26 Kennedy AS, Kleinstreuer C, Basciano CA. et al. Computer modeling of yttrium-90-microsphere transport in the hepatic arterial tree to improve clinical outcomes. Int J Radiat Oncol Biol Phys 2010; 76 (02) 631-637
    CrossrefPubMedGoogle Scholar
  • 27 Ho S, Lau WY, Leung TW. et al. Tumour-to-normal uptake ratio of 90Y microspheres in hepatic cancer assessed with 99Tcm macroaggregated albumin. Br J Radiol 1997; 70 (836) 823-828
    CrossrefPubMedGoogle Scholar
  • 28 Horsman MR, Overgaard J. The impact of hypoxia and its modification of the outcome of radiotherapy. J Radiat Res (Tokyo) 2016; 57 (Suppl. 01) i90-i98
    CrossrefPubMedGoogle Scholar
  • 29 Folkman J, Camphausen K. Cancer. What does radiotherapy do to endothelial cells?. Science 2001; 293 (5528): 227-228
    CrossrefPubMedGoogle Scholar
  • 30 Lewandowski RJ, Sato KT, Atassi B. et al. Radioembolization with 90Y microspheres: angiographic and technical considerations. Cardiovasc Intervent Radiol 2007; 30 (04) 571-592
    CrossrefPubMedGoogle Scholar
  • 31 Liu DM, Salem R, Bui JT. et al. Angiographic considerations in patients undergoing liver-directed therapy. J Vasc Interv Radiol 2005; 16 (07) 911-935
    CrossrefPubMedGoogle Scholar
  • 32 Bastiaannet R, Kappadath SC, Kunnen B. et al. The physics of radioembolization. EJNMMI Phys 2018; 5 (01) 22
    CrossrefPubMedGoogle Scholar
  • 33 Wasan HS, Gibbs P, Sharma NK. et al; FOXFIRE Trial Investigators, SIRFLOX Trial Investigators, FOXFIRE-Global Trial Investigators. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. Lancet Oncol 2017; 18 (09) 1159-1171
    CrossrefPubMedGoogle Scholar
  • 34 Abbott AM, Kim R, Hoffe SE. et al. Outcomes of TheraSphere radioembolization for colorectal metastases. Clin Colorectal Cancer 2015; 14 (03) 146-153
    CrossrefPubMedGoogle Scholar
  • 35 Salem R, Gabr A, Riaz A. et al. Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience. Hepatology 2018; 68 (04) 1429-1440
    CrossrefPubMedGoogle Scholar
  • 36 Chiesa C, Mira M, Maccauro M. et al. Radioembolization of hepatocarcinoma with (90)Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology. Eur J Nucl Med Mol Imaging 2015; 42 (11) 1718-1738
    CrossrefPubMedGoogle Scholar
  • 37 Mikell JK, Mahvash A, Siman W. et al. Comparing voxel-based absorbed dosimetry methods in tumors, liver, lung, and at the liver-lung interface for (90)Y microsphere selective internal radiation therapy. EJNMMI Phys 2015; 2 (01) 16
    CrossrefPubMedGoogle Scholar
  • 38 Wondergem M, Smits ML, Elschot M. et al. 99mTc-macroaggregated albumin poorly predicts the intrahepatic distribution of 90Y resin microspheres in hepatic radioembolization. J Nucl Med 2013; 54 (08) 1294-1301
    CrossrefPubMedGoogle Scholar
  • 39 Elschot M, Nijsen JF, Lam MG. et al. (99m)Tc-MAA overestimates the absorbed dose to the lungs in radioembolization: a quantitative evaluation in patients treated with 166Ho-microspheres. Eur J Nucl Med Mol Imaging 2014; 41 (10) 1965-1975
    CrossrefPubMedGoogle Scholar
  • 40 Yu N, Srinivas SM, Difilippo FP. et al. Lung dose calculation with SPECT/CT for 90yttrium radioembolization of liver cancer. Int J Radiat Oncol Biol Phys 2013; 85 (03) 834-839
    CrossrefPubMedGoogle Scholar
  • 41 Ilhan H, Goritschan A, Paprottka P. et al. Predictive value of 99mTc-MAA SPECT for 90Y-labeled resin microsphere distribution in radioembolization of primary and secondary hepatic tumors. J Nucl Med 2015; 56 (11) 1654-1660
    CrossrefPubMedGoogle Scholar
  • 42 Ulrich G, Dudeck O, Furth C. et al. Predictive value of intratumoral 99mTc-macroaggregated albumin uptake in patients with colorectal liver metastases scheduled for radioembolization with 90Y-microspheres. J Nucl Med 2013; 54 (04) 516-522
    CrossrefPubMedGoogle Scholar
  • 43 Garin E, Lenoir L, Edeline J. et al. Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept. Eur J Nucl Med Mol Imaging 2013; 40 (07) 1057-1068
    CrossrefPubMedGoogle Scholar
  • 44 Garin E, Rolland Y, Edeline J. et al. Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis. J Nucl Med 2015; 56 (03) 339-346
    CrossrefPubMedGoogle Scholar
  • 45 Gnesin S, Canetti L, Adib S. et al. Partition model based 99mTc-MAA SPECT/CT predictive dosimetry compared to 90Y TOF PET/CT post-treatment dosimetry in radioembolisation of hepatocellular carcinoma: a quantitative agreement comparison. J Nucl Med 2016; 57 (11) 1672-1678
    CrossrefPubMedGoogle Scholar
  • 46 Chansanti O, Jahangiri Y, Matsui Y. et al. Tumor dose response in yttrium-90 resin microsphere embolization for neuroendocrine liver metastases: a tumor-specific analysis with dose estimation using SPECT-CT. J Vasc Interv Radiol 2017; 28 (11) 1528-1535
    CrossrefPubMedGoogle Scholar
  • 47 Barbier CE, Garske-Román U, Sandström M. et al. Selective internal radiation therapy in patients with progressive neuroendocrine liver metastases. Eur J Nucl Med Mol Imaging 2016; 43 (08) 1425-1431
    CrossrefPubMedGoogle Scholar
  • 48 Braat AJAT, Kappadath SC, Ahmadzadehfar H. et al. Radioembolization with 90Y resin microspheres of neuroendocrine liver metastases: international multicenter study on efficacy and toxicity. Cardiovasc Intervent Radiol 2019; 42 (03) 413-425
    CrossrefPubMedGoogle Scholar
  • 49 Kennedy A, Bester L, Salem R. et al. PNET-Liver-Metastases Consensus Conference. Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver-Metastases Consensus Conference. HPB (Oxford) 2015; 17 (01) 29-37
    CrossrefPubMedGoogle Scholar
  • 50 Elf AK, Andersson M, Henrikson O. et al. Radioembolization versus bland embolization for hepatic metastases from small intestinal neuroendocrine tumors: short-term results of a randomized clinical trial. World J Surg 2018; 42 (02) 506-513
    CrossrefPubMedGoogle Scholar
  • 51 Devcic Z, Rosenberg J, Braat AJ. et al. The efficacy of hepatic 90Y resin radioembolization for metastatic neuroendocrine tumors: a meta-analysis. J Nucl Med 2014; 55 (09) 1404-1410
    CrossrefPubMedGoogle Scholar
  • 52 Frilling A, Clift AK, Braat AJAT. et al. Radioembolisation with 90Y microspheres for neuroendocrine liver metastases: an institutional case series, systematic review and meta-analysis. HPB (Oxford) 2019; 21 (07) 773-783
    CrossrefPubMedGoogle Scholar
  • 53 Jia Z, Wang W. Yttrium-90 radioembolization for unresectable metastatic neuroendocrine liver tumor: a systematic review. Eur J Radiol 2018; 100: 23-29
    CrossrefPubMedGoogle Scholar
  • 54 Chen JX, Rose S, White SB. et al. Embolotherapy for neuroendocrine tumor liver metastases: prognostic factors for hepatic progression-free survival and overall survival. Cardiovasc Intervent Radiol 2017; 40 (01) 69-80
    CrossrefPubMedGoogle Scholar
  • 55 Tsang ES, Loree JM, Davies JM. et al. Efficacy and prognostic factors for Y-90 radioembolization (Y-90) in metastatic neuroendocrine tumors with liver metastases. Can J Gastroenterol Hepatol 2020; 2020: 5104082
    CrossrefPubMedGoogle Scholar
  • 56 Zuckerman DA, Kennard RF. et al. Outcomes and toxicity following yttrium-90 radioembolization for hepatic metastases from neuroendocrine tumors-a single-institution experience. J Gastrointest Oncol 2019; 10 (01) 118-127
    CrossrefPubMedGoogle Scholar
  • 57 Kennedy AS, Dezarn WA, McNeillie P. et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol 2008; 31 (03) 271-279
    CrossrefPubMedGoogle Scholar
  • 58 Frilling A, Modlin IM, Kidd M. et al. Working Group on Neuroendocrine Liver Metastases. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol 2014; 15 (01) e8-e21
    CrossrefPubMedGoogle Scholar
  • 59 Vogl TJ, Naguib NN, Zangos S. et al. Liver metastases of neuroendocrine carcinomas: interventional treatment via transarterial embolization, chemoembolization and thermal ablation. Eur J Radiol 2009; 72 (03) 517-528
    CrossrefPubMedGoogle Scholar
  • 60 Engelman ES, Leon-Ferre R, Naraev BG. et al. Comparison of transarterial liver-directed therapies for low-grade metastatic neuroendocrine tumors in a single institution. Pancreas 2014; 43 (02) 219-225
    CrossrefPubMedGoogle Scholar
  • 61 Rhee TK, Lewandowski RJ, Liu DM. et al. 90Y radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Ann Surg 2008; 247 (06) 1029-1035
    CrossrefPubMedGoogle Scholar
  • 62 Memon K, Lewandowski RJ, Mulcahy MF. et al. Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes. Int J Radiat Oncol Biol Phys 2012; 83 (03) 887-894
    CrossrefPubMedGoogle Scholar
  • 63 Whitney R, Vàlek V, Fages JF. et al. Transarterial chemoembolization and selective internal radiation for the treatment of patients with metastatic neuroendocrine tumors: a comparison of efficacy and cost. Oncologist 2011; 16 (05) 594-601
    CrossrefPubMedGoogle Scholar
  • 64 Egger ME, Armstrong E, Martin II RC. et al. Transarterial chemoembolization vs radioembolization for neuroendocrine liver metastases: a multi-institutional analysis. J Am Coll Surg 2020; 230 (04) 363-370
    CrossrefPubMedGoogle Scholar
  • 65 Cao CQ, Yan TD, Bester L. et al. Radioembolization with yttrium microspheres for neuroendocrine tumour liver metastases. Br J Surg 2010; 97 (04) 537-543
    CrossrefPubMedGoogle Scholar
  • 66 Saxena A, Chua TC, Bester L. et al. Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumor liver metastases: a critical appraisal of 48 cases. Ann Surg 2010; 251 (05) 910-916
    CrossrefPubMedGoogle Scholar
  • 67 Bester L, Meteling B, Pocock N. et al. Radioembolisation with yttrium-90 microspheres: an effective treatment modality for unresectable liver metastases. J Med Imaging Radiat Oncol 2013; 57 (01) 72-80
    CrossrefPubMedGoogle Scholar
  • 68 Sangro B, Martínez-Urbistondo D, Bester L. et al. Prevention and treatment of complications of selective internal radiation therapy: expert guidance and systematic review. Hepatology 2017; 66 (03) 969-982
    CrossrefPubMedGoogle Scholar
  • 69 Devulapalli KK, Fidelman N, Soulen MC. et al. 90Y radioembolization for hepatic malignancy in patients with previous biliary intervention: multicenter analysis of hepatobiliary infections. Radiology 2018; 288 (03) 774-781
    CrossrefPubMedGoogle Scholar
  • 70 Su YK, Mackey RV, Riaz A. et al. Long-term hepatotoxicity of yttrium-90 radioembolization as treatment of metastatic neuroendocrine tumor to the liver. J Vasc Interv Radiol 2017; 28 (11) 1520-1526
    CrossrefPubMedGoogle Scholar
  • 71 Currie BM, Hoteit MA, Ben-Josef E. et al. Radioembolization-induced chronic hepatotoxicity: a single-center cohort analysis. J Vasc Interv Radiol 2019; 30 (12) 1915-1923
    CrossrefPubMedGoogle Scholar
  • 72 Tomozawa Y, Jahangiri Y, Pathak P. et al. Long-term toxicity after transarterial radioembolization with yttrium-90 using resin microspheres for neuroendocrine tumor liver metastases. J Vasc Interv Radiol 2018; 29 (06) 858-865
    CrossrefPubMedGoogle Scholar
  • 73 Sangro B, Gil-Alzugaray B, Rodriguez J. et al. Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer 2008; 112 (07) 1538-1546
    CrossrefPubMedGoogle Scholar
  • 74 Currie BM, Nadolski G, Mondschein J. et al. Chronic hepatotoxicity in patients with metastatic neuroendocrine tumor: transarterial chemoembolization versus transarterial radioembolization. J Vasc Interv Radiol 2020; 31 (10) 1627-1635
    CrossrefPubMedGoogle Scholar
  • 75 Kim HS, Shaib WL, Zhang C. et al. Phase 1b study of pasireotide, everolimus, and selective internal radioembolization therapy for unresectable neuroendocrine tumors with hepatic metastases. Cancer 2018; 124 (09) 1992-2000
    CrossrefPubMedGoogle Scholar
  • 76 Soulen MC, van Houten D, Teitelbaum UR. et al. Safety and feasibility of integrating yttrium-90 radioembolization with capecitabine-temozolomide for grade 2 liver-dominant metastatic neuroendocrine tumors. Pancreas 2018; 47 (08) 980-984
    CrossrefPubMedGoogle Scholar
  • 77 King J, Quinn R, Glenn DM. et al. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer 2008; 113 (05) 921-929
    CrossrefPubMedGoogle Scholar
  • 78 Food and Drug Administration. FDA approves lutetium Lu 177 dotatate for treatment of GEP-NETS. Accessed January 26, 2018 at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208700s000lbl.pdf
    PubMedGoogle Scholar
  • 79 Strosberg J, El-Haddad G, Wolin E. et al; NETTER-1 Trial Investigators. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med 2017; 376 (02) 125-135
    CrossrefPubMedGoogle Scholar
  • 80 Brabander T, van der Zwan WA, Teunissen JJM. et al. Long-term efficacy, survival, and safety of [177Lu-DOTA0, Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin Cancer Res 2017; 23 (16) 4617-4624
    CrossrefPubMedGoogle Scholar
  • 81 Hamiditabar M, Ali M, Bolek L. et al. Safety and effectiveness of 177Lu-DOTATATE peptide receptor radionuclide therapy after regional hepatic embolization in patients with somatostatin-expressing neuroendocrine tumors. Clin Nucl Med 2017; 42 (11) 822-828
    CrossrefPubMedGoogle Scholar
  • 82 Riff BP, Yang YX, Soulen MC. et al. Peptide receptor radionuclide therapy-induced hepatotoxicity in patients with metastatic neuroendocrine tumors. Clin Nucl Med 2015; 40 (11) 845-850
    CrossrefPubMedGoogle Scholar
  • 83 Braat AJAT, Ahmadzadehfar H, Kappadath SC. et al. Radioembolization with 90Y resin microspheres of neuroendocrine liver metastases after initial peptide receptor radionuclide therapy. Cardiovasc Intervent Radiol 2020; 43 (02) 246-253
    CrossrefPubMedGoogle Scholar
  • 84 Aras M, Erdil TY, Dane F. et al. Comparison of WHO, RECIST 1.1, EORTC, and PERCIST criteria in the evaluation of treatment response in malignant solid tumors. Nucl Med Commun 2016; 37 (01) 9-15
    CrossrefPubMedGoogle Scholar
  • 85 Therasse P, Arbuck SG, Eisenhauer EA. et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92 (03) 205-216
    CrossrefPubMedGoogle Scholar
  • 86 Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30 (01) 52-60
    Article in Thieme ConnectPubMedGoogle Scholar